SavedAdd your journal

Journals / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2015 / Cilt: 49 - Sayı: 1

A case of lenflunomide-induced alopecia areata

Lenflunomide bağlı bir alopesi areata olgusu

Ercan ÇALIŞKAN
Gürol AÇIKGÖZ
Yıldıray YENİAY
Ercan ARCA
Pages
78–80
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this case report, we present a 38-year-old male patient who suffered from alopecia areata after leflunomide therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Leflunomide is an immunomodulatory drug widely used in the treatment of inflammatory arthritis, especially in rheumatoid arthritis and psoriatic arthritis.
📊
Key Findings & Data:The common side effects of leflunomide are hepatopathy, hypertension, various gastrointestinal complaints and transient hair loss, which are all mild and reversible.
💡
Conclusion & Impact:In this case report, we present a 38-year-old male patient who suffered from alopecia areata after leflunomide therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Leflunomide is an immunomodulatory drug widely used in the treatment of inflammatory arthritis, especially in rheumatoid arthritis and psoriatic arthritis. The common side effects of leflunomide are hepatopathy, hypertension, various gastrointestinal complaints and transient hair loss, which are all mild and reversible. Although leflunomide is associated with transient hair loss, only one case of leflunomide-induced alopecia areata has been reported previously. In this case report, we present a 38-year-old male patient who suffered from alopecia areata after leflunomide therapy.

Özet

Leflunomid, özellikle romatoid artrit ve psoriatik artrit başta olmak üzere inflamatuvar artritlerin tedavisinde yaygın olarak kullanılan immünomodülatuvar bir ilaçtır. Lenflunomidin yan etkileri genellikle hafif ve geçici özellik göstermekle birlikte en sık izlenen yan etkileri hepatopati, hipertansiyon, gastrointestinal rahatsızlıklar ve geçici saç kaybıdır. Leflunomide bağlı geçici saç kaybı oluşabileceği bildirilmiş olmasına karşın, alopesi areata gelişimi bugüne kadar sadece bir olguda bildirilmiştir. Bu olgu sunumunda, leflunomid tedavisi sonrasında alopesi areata gelişen 38 yaşında bir erkek hastayı sunuyoruz.

🔖

Cite This Article

ÇALIŞKAN, E., AÇIKGÖZ, G., YENİAY, Y., ARCA, E. (2022). A case of lenflunomide-induced alopecia areata. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 49 - Sayı: 1, 78–80. https://ajindex.com/articles/621795

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Breedveld FC, Dayer JM: Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000;59:841-9
  2. Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, Wells G: Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2003;30:1182-90
  3. Boyd AS: Leflunomide in dermatology. J Am Acad Dermatol 2012;66:673-9
  4. Ochi S, Taniguchi K, Nagashima M: Leflunomide-induced polymyositis in a patient with rheumatoid arthritis. Mod Rheumatol 2009;19:443-6
  5. Sharma VK, Dawn G, Kumar B: Profile of alopecia areata in Northern India. Int J Dermatol 1996;35:22-7
  6. Tan E, Tay YK, Goh CL, Chin Giam Y: The pattern and profile of alopecia areata in Singapore-a study of 219 Asians. Int J Dermatol 2002;41:748-53
  7. Ito T: Recent advances in the pathogenesis of autoimmune hair loss disease alopecia areata. Clin Dev Immunol 2013;2013:348546
  8. Neila J, Carrizosa A, Ceballos C, Camacho FM: [Alopecia areata after biologic therapy: report of a case related to adalimumab]. Actas Dermosifiliogr 2011;102:827-8
  9. Beccastrini E, Squatrito D, Emmi G, Fabbri P, Emmi L: Alopecia areata universalis during off-label treatment with Infliximab in a patient with Behçet disease. Dermatol Online J 2010;16:15
  10. Pan Y, Rao NA: Alopecia areata during etanercept therapy. Ocul Immunol Inflamm 2009;17:127-9
  11. Gottenberg JE, Venancie PY, Mariette X: Alopecia areata in a patient with rheumatoid arthritis treated with leflunomide. J Rheumatol 2002;29:1806-7
  12. Shafa S, Borum ML, Igiehon E: A case of irreversible alopecia associated with ribavirin and peg-interferon therapy. Eur J Gastroenterol Hepatol 2010;22:122-3
  13. Ettefagh L, Nedorost S, Mirmirani P: Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles. Arch Dermatol 2004;140:1012
  14. Afzali B, Lombardi G, Lechler RI, Lord GM: The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007;148:32-46
  15. Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA: Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology 2006;117:433-42
  16. Tembhre MK, Sharma VK: T-helper and regulatory T-cell cytokines in the peripheral blood of patients with active alopecia areata. Br J Dermatol 2013;169:543-8
  17. Oh JS, Kim YG, Lee SG, So MW, Choi SW, L